D. Boral Capital Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

D. Boral Capital reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research note released on Tuesday,Benzinga reports. D. Boral Capital currently has a $2.00 target price on the stock.

Several other equities research analysts have also recently weighed in on the stock. Maxim Group lowered their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Tuesday, February 11th.

Lineage Cell Therapeutics Stock Down 0.0 %

Shares of LCTX stock opened at $0.52 on Tuesday. Lineage Cell Therapeutics has a 12-month low of $0.48 and a 12-month high of $1.61. The company has a market cap of $114.62 million, a P/E ratio of -4.33 and a beta of 1.21. The company’s 50-day moving average price is $0.60.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new stake in shares of Lineage Cell Therapeutics during the 4th quarter worth approximately $46,000. Two Sigma Advisers LP grew its holdings in Lineage Cell Therapeutics by 312.2% during the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after purchasing an additional 65,864 shares during the period. Two Sigma Investments LP acquired a new position in Lineage Cell Therapeutics during the fourth quarter valued at approximately $152,000. Jacobs Levy Equity Management Inc. acquired a new position in Lineage Cell Therapeutics during the fourth quarter valued at approximately $519,000. Finally, Deutsche Bank AG grew its holdings in Lineage Cell Therapeutics by 196.0% during the fourth quarter. Deutsche Bank AG now owns 174,702 shares of the company’s stock valued at $87,000 after purchasing an additional 115,672 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.